Ability Pharma begins phase 2 of the antitumor drug ABTL0812

The Parc company has started clinical trials of Phase II of its new antitumor drug ABTL0812, for the treatment of advanced endometrial cancer and squamous cell lung cancer, in combination with other chemotherapies such as Paclitaxel and Carboplatin. The company, led by its co-founder, Dr. Carles Domènech, reached an agreement in April to license the drug to SciClones Pharmaceuticals, a US company.